Effect of dexmedetomidine and midazolam for flexible fiberoptic bronchoscopy in intensive care unit patients
A retrospective study
Yang Gao, MS\textsuperscript{a}, Kai Kang, MD\textsuperscript{b}, Haitao Liu, MD\textsuperscript{c}, Liu Jia, MS\textsuperscript{a}, Rong Tang, MS\textsuperscript{a}, Xing Zhang, MS\textsuperscript{a}, Hongliang Wang, MD\textsuperscript{a,\textdagger}, Kailiang Yu, MS\textsuperscript{a,\textdagger}\textasteriskcentered

Abstract
This study aimed to investigate the clinical effectiveness of dexmedetomidine and midazolam for sedation of intensive care unit (ICU) patients requiring flexible fiberoptic bronchoscopy (FFB).

This retrospective cohort study included 148 patients from the third ICU ward of the Second Affiliated Hospital of Harbin Medical University (Harbin, China) who received simultaneous invasive mechanical ventilation and FFB between March 2012 and December 2014. Patients were divided into dexmedetomidine (n = 72) and midazolam (n = 76) groups according to sedative mode. The sedative effects, incidence of adverse events, and bronchoscopist satisfaction scores were compared between groups.

During FFB, total sedation time and total time of FFB were significantly shorter in the midazolam group (\(P < .001\), respectively), with a lower percentage of these patients requiring propofol for remedial sedation (\(P < .001\)). The incidence of FFB-related adverse events (including bronchospasm, cough, and decreased oxygen saturation) was significantly higher in dexmedetomidine group compared with midazolam group (\(P = .007, .014\) and \(P = .008\), respectively). However, the incidence of other adverse events was not significantly different between groups. In addition, bronchoscopist satisfaction scores were significantly higher in the midazolam compared with dexmedetomidine group (7.72 ± 1.65 vs 7.08 ± 1.77; \(P = .030\)).

For sedation of ICU patients during FFB, combination of midazolam and dexmedetomidine demonstrated an enhanced sedative effect, lower incidence of adverse events, and higher bronchoscopist satisfaction score compared with dexmedetomidine alone, thus represents a suitable alternative sedative for FFB patients.

Abbreviations: APACHE = acute physiology and chronic health evaluation, BP = blood pressure, FFB = flexible fiberoptic bronchoscopy, HR = heart rate, ICU = intensive care unit, RASS = Richmond Agitation Sedation Scale, SPO\textsubscript{2} = decreased oxygen saturation.

Keywords: bronchoscopy, deep sedation, dexmedetomidine, midazolam

1. Introduction
Flexible fiberoptic bronchoscopy (FFB) is widely used in intensive care unit (ICU) patients and is considered a safe and effective procedure that allows direct airway observation. Although FFB is predominantly used for the diagnosis and treatment of respiratory diseases in critically ill patients\textsuperscript{[1,2]} the invasive nature of this technology can induce cough, dyspnea, airway reflex contraction, laryngospasm, and catecholamine release, with further detrimental effects on patient prognosis\textsuperscript{[3]} Consequently, the American College of Chest Physicians has highlighted the necessity of using sedation combined with topical anesthesia during FFB\textsuperscript{[4]} Appropriate sedation and analgesia during this procedure can improve patient tolerance and comfort, reduce fear, anxiety, and mental stress, and improve overall clinical outcome\textsuperscript{[1,5]}

Disease conditions of many ICU patients requiring FFB are often complex, with the majority of patients being on mechanical ventilation. Consequently, these patients are less likely to tolerate FFB stimulation; therefore, deeper sedation is needed to ensure a successful procedure and reduce the risk of adverse events. However, insufficient sedation can induce severe discomfort and further damage in patients\textsuperscript{[5]}
At present, no guidelines exist for the selection and use of sedatives for FFB. The most commonly used sedatives in clinical practice include dexmedetomidine and midazolam. Previous studies have shown that dexmedetomidine is more effective in conscious and light sedation. Dexmedetomidine can be used for long-term sedation during mechanical ventilation in critically ill patients, which can reduce the ventilation time and ICU stay. Furthermore, dexmedetomidine can provide appropriate anesthesia depth and ideal conditions for rigid bronchoscopic airway removal of foreign bodies in children. However, there are no studies to date that have compared the sedative effects and adverse reactions of different sedatives during FFB in critically ill ICU patients on mechanical ventilation. In the present study, the clinical effectiveness of dexmedetomidine and midazolam for sedation of ICU patients before FFB was compared.

2. Materials and methods

2.1. Study design

The present study is a retrospective cohort study.

2.2. Study population

Patient inclusion criteria included: ICU patients receiving invasive mechanical ventilation and requiring FFB in the third ICU ward of the Second Affiliated Hospital of Harbin Medical University between March 2012 and December 2014; aged >18 years; and stable hemodynamics. Patient exclusion criteria included: hypoxemia; left ventricular ejection fraction <0.30, heart rate (HR) <50 beats/min, grade II–III cardiac conduction block, or pathologic sinus sick syndrome; unstable angina pectoris or acute myocardial infarction; Glasgow Coma Scale score ≤8; loss of hearing; combined severe complications such as diabetic ketoacidosis, liver failure, renal failure, and so on; neuromuscular transmission failure; women in gestation or breastfeeding; blood purifiation treatment; psychological diseases, or long-term use or addiction to antipsychotics; long-term use of sedative drugs; and allergy to the sedatives or analgesics used in the study. Written informed consent was obtained from all patient families before carrying out FFB. Patients were divided into 2 groups according to the sedatives used.

2.3. Sedation and analgesia

2.3.1. Drug selection. Fentanyl citrate injection (2 mL [0.1 mg]/ampoule, Renfu Pharmaceutical Co., Ltd., Yichang) was used as the analgesia. The following drugs were used for sedation: dexmedetomidine hydrochloride injection (2 mL [200 μg]/ampoule, Hengrui Pharmaceutical Co., Ltd, Jiangsu; period of validity: 18 months); midazolam injection (2 mL [10 mg]/ampoule, Enhua Pharmaceutical Co., Ltd; period of validity: 36 months); and propofol injection (50 mL [1 g]/ampoule, Fresenius KabiPharmaceutical Co., Ltd, Beijing; period of validity: 36 months).

2.3.2. Drug administration. All drugs were administered after recovery of the patients’ conscious or reaching 0 score of the Richmond Agitation Sedation Scale (RASS). Endoscopic dripping of 2% lidocaine (3–5 mg/kg) was used for topical anesthesia, and then intravenous injection of fentanyl citrate (2.0 μg/kg) was administered. Dexmedetomidine hydrochloride injection with a loading dose of 0.8 μg/kg was used for intravenous pumping for 10 minutes, after which the dose was switched to 0.2 to 0.7 μg/kg/h for maintenance. Midazolam injection with a loading dose of 0.05 mg/kg was used for intravenous pumping for 10 minutes, after which the dose was switched to 0.02 to 0.2 mg/kg/h for maintenance. RASS score was obtained every 5 minutes, and the drug dose was adjusted accordingly until it reached a satisfactory deep sedation level with an RASS score of −3 to −4. Propofol injection with a loading dose of 2.0 mg/kg could also be used for intravenous injection and switched to 0.5 to 4 mg/kg/h for remedial sedation if necessary. After completion of FFB, further sedation and analgesia could be continued after the patient’s conditions were evaluated. For patients with severe adverse reactions during FFB, the procedure was discontinued and symptomatic treatment was provided. The disease conditions were then evaluated to determine whether the procedure could be continued.

2.4. Invasive mechanical ventilation

All patients received electrocardiogram monitoring, invasive artery blood pressure (BP) monitoring, and decreased oxygen saturation (SpO2) monitoring (Mindray monitoring device, BeneView T8). Ventilator parameters were set to maintain the SpO2 >90% during FFB, otherwise examinations were discontinued.

2.5. Fiberoptic bronchoscopy

A fiberoptic bronchoscope (Olympus LF-TP, Japan) was used in accordance with standardized procedures.

2.6. Data collection

2.6.1. Baseline data. Sex, age, height, weight, acute physiology and chronic health evaluation (APACHE) II score, and indications for FFB were obtained from patient medical records.

2.6.2. Sedative effects. Total sedation time, time of bedside FFB, frequencies of remedial sedation by propofol, and incidence of adverse events (including cough, nausea, and bronchospasm) were collected. – (HR), BP, respiration rate, and SpO2 were recorded every five minutes.

2.6.3. Bronchoscopic satisfaction scores. After completion of FFB, bronchoscopic sedation satisfaction scores were recorded for all patients (“0” indicated very unsatisfied and “10” indicated very satisfied).

2.7. Statistical analyses

SPSS 22.0 (SPSS Inc, Chicago, IL) and SAS 9.1 (SAS Institute, Cary, NC) software were used for statistical analysis. Quantitative data are shown as means ± standard deviations and qualitative data are shown as percentages. The Student t test and Mann-Whitney U test were used to compare quantitative data between groups, whereas the χ2 test was used to compare qualitative data between groups. P < .05 was considered to be statistically significant.

3. Results

3.1. Patient baseline data

There were no significant differences in patient baseline data between groups (P > .05, Table 1).
Table 1

| Parameter                  | Dexmedetomidine group (n = 72) | Midazolam group (N = 76) | P     |
|----------------------------|--------------------------------|--------------------------|-------|
| Sex male (%)               | 42 (58.3)                      | 37 (48.7)                | .240  |
| Age, y                     | 58.03 ± 10.47                  | 59.25 ± 11.54            | .367  |
| Height, cm                 | 167.64 ± 8.53                  | 169.17 ± 8.89            | .710  |
| Weight, kg                 | 67.68 ± 8.62                   | 66.32 ± 9.94             | .232  |
| APACHE II score            | 17.54 ± 4.62                   | 16.75 ± 4.44             | .219  |

Table 2

Sedative effects during fiberoptic bronchoscopy.

| Parameter                  | Dexmedetomidine group (n = 72) | Midazolam group (n = 76) | P     |
|----------------------------|--------------------------------|--------------------------|-------|
| Examination diagnosis (%)  | 21 (29.2)                      | 27 (35.5)                | .409  |
| Bronchoalveolar lavage (%) | 51 (70.8)                      | 49 (64.5)                |       |

Table 3

Incidence of fiberoptic bronchoscopy-related adverse events.

| Parameter                  | Dexmedetomidine group (n = 72) | Midazolam group (n = 76) | P     |
|----------------------------|--------------------------------|--------------------------|-------|
| Cough                      | 41 (56.9)                      | 28 (36.8)                | .014  |
| Nausea                     | 12 (16.7)                      | 13 (17.1)                | .943  |
| Bronchospasm               | 49 (68.1)                      | 35 (46.1)                | .007  |
| Tachycardia                | 21 (29.2)                      | 25 (32.9)                | .624  |
| Arrhythmia                 | 5 (6.9)                        | 6 (7.9)                  | .826  |
| SpO2 decrease              | 32 (44.4)                      | 18 (23.7)                | .008  |
| Hypertension               | 11 (15.3)                      | 12 (15.8)                | .932  |
| Others                     | 4 (5.6)                        | 6 (7.9)                  | .571  |

Although FFB is invasive, it lacks standardization, particularly with respect to sedative selection and application, resulting in vast clinical differences. Each sedative has its own advantages and disadvantages when applied in clinic. For ICU patients requiring bedside FFB, identifying an optimal sedation and analgesia strategy with good sedative effect, low risk of adverse events, high bronchoscopist satisfaction score, and high operability is important. Very few studies have addressed this clinical issue; therefore, the present study compared the clinical effectiveness and safety profile of 2 commonly used sedatives during FFB.

Before FFB, all analgesic and sedative drugs were discontinued until recovery of the patients’ conscious or reaching 0 score of the RASS. All patients received 2% lidocaine (3–5 mg/kg) as a topical anesthesia to reduce the incidence of coughing and the required dose of intravenous sedative. Fentanyl citrate, a synthesized phenyl piperidine drug, was also administered to all patients. This narcotic analgesic drug is commonly used in clinical practice because it has a relatively weak respiratory inhibition effect and can inhibit stress reactions of the cardiovascular system. During FFB of ICU patients, common intravenous sedatives include propofol, dexmedetomidine, and midazolam. Propofol is a short-acting intravenous sedation drug that elicits sedation, hypnosis, and amnesia effects. The advantages of propofol include its fast-acting and -elimination properties, as well as its promotion of laryngeal reflex inhibition and bronchial smooth muscle dilation. The disadvantages of propofol include transient dose-dependent respiration and circulation inhibition, and an elevated risk of delirium.

Dexmedetomidine is a new α2 adrenergic receptor agonist with high efficiency and selectivity which can bind to the α2 receptor in brain and spinal cord, reduce the plasma concentration of catecholamine, and exert sedative, anti-anxiety and analgesic effects.

3.2. Sedative effects

As shown in Table 2, total sedation time and time of bedside FFB were significantly shorter in the midazolam group compared with the dexmedetomidine group (P < .001, respectively). The frequency and percentage of patients that used propofol for remedial sedation were significantly higher in the dexmedetomidine group compared with the midazolam group (P < .001). The incidence of FFB-related adverse events (including bronchospasm, cough, and decreased SpO2) was significantly higher in the dexmedetomidine group compared with the midazolam group (P = .007, .014, 0.008, respectively, Table 3). When assessed individually, the incidence of decreased SpO2 was significantly higher in the dexmedetomidine group compared with the midazolam group (P = .008); however, the incidence of other adverse events was not significantly different between groups (Table 4).

3.3. Bronchoscopist satisfaction score

After completion of FFB, the mean bronchoscopist satisfaction scores were 7.08 ± 1.77 and 7.72 ± 1.65 in the dexmedetomidine and midazolam groups, respectively (P = .030, Table 2).

4. Discussion

FFB can cause cough, shortness of breath, and irritation of the nose and throat, which in turn can stimulate the release of catecholamine, leading to tachycardia, vasoconstriction, and myocardial ischemia in patients with impaired cardiopulmonary function. In short, the influence of this technique in ICU patients can ultimately lead to worse respiratory cycle. FFB is more invasive and painful than other techniques; sedation can reduce patient anxiety and pain, and enhance comfort, thus reducing further serious injury.

Table 4

| Parameter                  | Dexmedetomidine group (n = 72) | Midazolam group (n = 76) | P     |
|----------------------------|--------------------------------|--------------------------|-------|
| Nausea                     | 12 (16.7)                      | 13 (17.1)                | .943  |
| Tachycardia                | 21 (29.2)                      | 25 (32.9)                | .624  |
| Bradycardia                | 7 (9.7)                        | 5 (6.9)                  | .614  |
| Arrhythmia                 | 5 (6.9)                        | 6 (7.9)                  | .826  |
| SpO2 decrease              | 32 (44.4)                      | 22 (15.0)                | .008  |
| Hypertension               | 11 (15.3)                      | 12 (15.8)                | .932  |
| Others                     | 4 (5.6)                        | 6 (7.9)                  | .571  |

SP02 = decreased oxygen saturation.
effects. Additionally, this drug has an anti-sialic effect and can induce retrograde amnesia and reduce the incidence of delirium. Dexmedetomidine activates the α2 adrenergic receptor at the pre- and postsynaptic membranes of ganglia in the brain and spinal cord, which would in turn inhibit sympathetic nerve excitation, enhance vagal nerve activity, and induce bradycardia, thus decreasing BP. Midazolam is a fast-acting sedative drug, which can also induce hypnosis, anti-anxiety, and retrograde amnesia, with dose-dependent effects on the respiratory and circulatory systems. However, when used in patients with liver and/or renal dysfunction, the risks of drug accumulation and delirium are relatively high.ORT During FFB, intravenous injection of dexmedetomidine can not only prevent the bronchial constriction induced by the release of histamine, and reduce airway responsiveness, but can also inhibit excitation of the sympathetic nervous system, and maintain stable response hormones at low-level during the procedure, and enhance the comfort and compliance of patients. The effect of dexmedetomidin in conscious sedation and maintaining light sedation is more pronounced and can be applied to critically ill patients, but the effect in medium-to-depth sedation is unknown. Moderate sedatives have been increasingly used to improve patient comfort during flexible bronchoscopy (FB). However, the findings of the present study showed that the sedative effects, incidence of adverse events, and bronchoscopist satisfaction scores were superior in midazolam group compared with dexmedetomidine group. In addition, the use of dexmedetomidine alone did not provide a sufficient sedative effect, which could be associated with the following factors. First, all patients were critically ill and on mechanical ventilation, therefore were less likely to tolerate FFB stimuli, thus a deeper sedation target (RASS score of −3 to −4) was needed to eliminate adverse stimulations. However, an advantage of dexmedetomidine is that it provides conscious and light sedation, thus improving its clinical and economic values.

In the present study, the dexmedetomidine dose did not reach the target depth of sedation; therefore, the percent of propofol usage for remedial sedation was higher, which is in agreement with results reported by Lee et al. Second, the FFB stimulation intensity was underestimated by the majority of clinicians. Third, the complications that arose in the study may have been because of both the FFB procedure and the drug type used, which may affect overall patient judgment. Finally, the eligibility criteria were very strict, with many exclusion criteria applied; consequently, the sample size was relatively small. Future studies comprising larger sample sizes are needed to verify our findings.

5. Conclusions In summary, the present study shows that when used alone, dexmedetomidine is suitable for conscious sedation and maintaining light sedation. However, for invasive procedures requiring relatively high stimulations, drug combinations could help maintain sufficient sedative depth and bronchoscopist satisfaction score, reduce adverse reactions, and thus improve patient comfort and safety. And this may provide insight and help for better sedation and clinical outcomes.

Acknowledgment The authors thank the participants and colleagues from the third ICU ward of the Second Affiliated Hospital of Harbin Medical University, and all the people who offer the advice and help to this study.

References

[1] Sriratanaviriyakul N, Lam F, Morrissey BM, et al. Safety and clinical utility of flexible bronchoscopic cryoextraction in patients with non-neoplastic tracheobronchial obstruction: a retrospective chart review. J Bronchology Interv Pulmonol 2015;22:288–93.
[2] Stahl DL, Richard KM, Papadimos TJ. Complications of bronchoscopy: a concise synopsis. Int J Crit Illn Inj Sci 2015;5:189–95.
[3] Kar Kurt O, Talay F, Kargi A, et al. Sedation for fiberoptic bronchoscopy: review of the literature. Tuberk Toraks 2015;63:42–7.
[4] Wahidi MM, Jain P, Jantz M, et al. American College of Chest Physicians consensus statement on the use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy in adult patients. Chest 2011;140:1342–50.
[5] Sugawara T, Takeda T, Shirakami G. Monitored anesthesia care for respiratory endoscopy. Masui 2015;64:263–9.
[6] Josi RJ, Shaef S, Navani N. Sedation for flexible bronchoscopy: current and emerging evidence. Eur Respir Rev 2013;22:106–16.
[7] Mondal S, Ghosh S, Bhattacharya S, et al. Comparison between dexmedetomidine and fentanyl on intubation conditions during awake fiberoptic bronchoscopy: a randomized double-blind prospective study. J Anaesthesiol Clin Pharmacol 2015;31:212–6.
[8] Fraser GL, Devlin JW, Worby CP, et al. Benzodiazipine versus nonbenzodiazipine-based sedation for mechanically ventilated, critically ill adults: a systematic review and meta-analysis of randomized trials. Crit Care Med 2013;41:9 suppl 1:S30–38.
[9] Chen K, Lu Z, Xin YC, et al. Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. Cochrane Database Syst Rev 2015;1:CD010269.
[10] Cai Y, Li W, Chen K. Efficacy and safety of spontaneous ventilation technique using dexmedetomidine for rigid bronchoscopic airway foreign body removal in children. Paediatr Anaesth 2013;23:1048–53.
[11] Chalumeau-Lemene L, Stoclin A, Billard V, et al. Flexible fiberoptic bronchoscopy and remifentanil target-controlled infusion in ICU: a preliminary study. Intensive Care Med 2013;39:53–6.
[12] Barnett AM, Jones R, Simpson G. A survey of bronchoscopy practice in Australia and New Zealand. J Bronchology Interv Pulmonol 2016;23:22–8.
[13] Hautmann H, Hertzl J, Eberhardt R, et al. Cross-sectional survey on bronchoscopy in Germany—The Current Status of Clinical Practice. Pneumologie 2016;70:110–6.
[14] Antoniades N, Worsnop C, Jones R, et al. Topical lidocaine through the bronchoscope: review of the literature. Tuberk Toraks 2015;63:42–7.
[15] Hanazaki M, Yokoyama M, Morita K, et al. Rho-kinase inhibitors augment the inhibitory effect of propofol on rat bronchial smooth muscle contraction. Anesth Analg 2000;90:1765–71.
[16] Sakurai Y, Obata T, Odaka A, et al. Buccal administration of dexmedetomidine as a preanesthetic in children. J Anesth 2010;24:49–53.
[17] Riker RR, Fraser GL. Altering intensive care sedation paradigms to improve patient outcomes. Anesthesiol Clin 2011;29:663–74.
[18] Dasta JF, Kane-Gill SL, Pencina M, et al. A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit. Crit Care Med 2010;38:497–503.
[19] Ihmsen H, Saari TI. Dexmedetomidine. Pharmacokinetics and pharmacodynamics. Anaesthesist 2012;61:1059–66.
[20] Afonso J, Reis F. Dexmedetomidine: current role in anesthesia and intensive care. Rev Bras Anestesiol 2012;62:118–33.
[21] Li B, Wang H, Wu H, et al. Neurocognitive dysfunction risk alleviation with the use of dexmedetomidine in perioperative conditions or as ICU sedation: a meta-analysis. Medicine (Baltimore) 2015;94:e597.
[22] Constantin JM, Momon A, Manzt J, et al. Efficacy and safety of sedation with dexmedetomidine in critical care patients: a meta-analysis of randomized controlled trials. Anaesth Crit Care Pain Med 2016;35:7–15.
[23] Patel SB, Kress JP. Sedation and analgesia in the mechanically ventilated patient. Am J Respir Crit Care Med 2012;185:486–97.
[24] Pandharipande P, Cotton BA, Shintani A, et al. Prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients. J Trauma 2008;65:34–41.
[25] Turunen H, Jakob SM, Ruokonen E, et al. Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care: an economic evaluation. Crit Care 2015;19:67.
[26] Lam SW, Alexander E. Dexmedetomidine use in critical care. AACN Adv Crit Care 2008;19:113–20.
[27] Gupta A, Lee D, Su M. Comparing dexmedetomidine with midazolam for sedation of patients in the ICU. Jama 2009;301:2440–1.
[28] Bergese SD, Candotti KA, Bokesch PM, et al. A Phase IIIb, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of dexmedetomidine for sedation during awake fiberoptic intubation. Am J Ther 2010;17:586–95.
[29] Jain G, Ransal P, Ahmad B, et al. Effect of the perioperative infusion of dexmedetomidine on chronic pain after breast surgery. Indian J Palliat Care 2012;18:45–51.
[30] Hong KS, Cho Y, Park DA, et al. Safety and efficacy of the moderate sedation during flexible bronchoscopic procedure: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2013;92:e1439.
[31] Liao W, Ma G, Su QG, et al. Dexmedetomidine versus midazolam for conscious sedation in postoperative patients undergoing flexible bronchoscopy: a randomized study. J Int Med Res 2012;40:1371–80.
[32] Gupta S, Singh D, Sood D, et al. Role of dexmedetomidine in early extubation of the intensive care unit patients. J Anaesthesiol Clin Pharmacol 2015;31:92–8.
[33] Ahmed S, Murugan R. Dexmedetomidine use in the ICU: are we there yet? Crit Care 2013;17:320.
[34] Lachaine J, Beauchemin C. Economic evaluation of dexmedetomidine relative to midazolam for sedation in the intensive care unit. Can J Hosp Pharm 2012;65:103–10.
[35] Lee K, Orme R, Williams D, et al. Prospective pilot trial of dexmedetomidine sedation for awake diagnostic flexible bronchoscopy. J Bronchology Interv Pulmonol 2010;17:323–8.